Highlights
NASDAQ: ONCY       Oncolytics Biotech Inc
Last Price Today's Change   Day's Range   Trading Volume
1.05   +0.03 (2.94%)  1.02 - 1.11  387,600

Overview

 
Avg Volume (4 weeks):911,242
4 Weeks Range:0.46 - 1.47
4 Weeks Price Volatility (%):
58.42%
52 Weeks Range:0.35 - 2.772
52 Weeks Price Volatility (%):
28.90%
Average Price Target:-

Headlines



No recent Headlines for this stock.


Business Background

Oncolytics Biotech Inc. (Oncolytics) is a development-stage company. The Company is focused on research and development of REOLYSIN, which is its cancer therapeutic. REOLYSIN is developed from reovirus. Oncolytics is directing a clinical trial program with the focus of developing REOLYSIN as a human cancer therapeutic. The clinical program includes clinical trials, which it sponsors directly along with Third Party Clinical Trials. Third Party Clinical Trials are clinical trials that are being sponsored by other institutions. Its clinical trial program includes human trials using REOLYSIN alone, and in combination with radiation and chemotherapy, and delivered via local administration and/or intravenous administration. Oncolytics uses contract toll manufacturers to produce REOLYSIN. The Company has two subsidiaries: Oncolytics Biotech (Barbados) Inc. (OBB), a Barbados company, and Valens Pharma Ltd. Oncolytics Biotech (US) Inc. and Oncolytics Biotech (U.K.) are subsidiaries of OBB.

  Be the first to like this.
 


 

4486  3499  717  224 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 CHK 0.702+0.032 
 FCEL 0.81+0.265 
 AMD 37.52+0.81 
 EEM 42.76-0.33 
 ET 11.16-0.50 
 SPY 309.10+0.10 
 GE 11.29-0.13 
 BAC 32.79-0.30 
 DIS 148.72+10.14 
 XLF 29.61-0.19 
Partners & Brokers